- Home
- VTEX vs OCS Comparison
VTEX vs OCS Comparison
Compare VTEX & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTEX
- OCS
- Stock Information
- Founded
- VTEX 1999
- OCS 2003
- Country
- VTEX Cayman Islands
- OCS Switzerland
- Employees
- VTEX N/A
- OCS N/A
- Industry
- VTEX Computer Software: Prepackaged Software
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- VTEX Technology
- OCS Health Care
- Exchange
- VTEX Nasdaq
- OCS Nasdaq
- Market Cap
- VTEX 1.1B
- OCS 956.4M
- IPO Year
- VTEX 2021
- OCS N/A
- Fundamental
- Price
- VTEX $4.08
- OCS $17.40
- Analyst Decision
- VTEX Buy
- OCS Strong Buy
- Analyst Count
- VTEX 4
- OCS 4
- Target Price
- VTEX $7.83
- OCS $35.75
- AVG Volume (30 Days)
- VTEX 1.3M
- OCS 13.6K
- Earning Date
- VTEX 11-04-2025
- OCS 11-06-2025
- Dividend Yield
- VTEX N/A
- OCS N/A
- EPS Growth
- VTEX 48.79
- OCS N/A
- EPS
- VTEX 0.05
- OCS N/A
- Revenue
- VTEX $230,497,000.00
- OCS $960,668.00
- Revenue This Year
- VTEX $11.14
- OCS $11.49
- Revenue Next Year
- VTEX $15.19
- OCS $1,784.02
- P/E Ratio
- VTEX $78.64
- OCS N/A
- Revenue Growth
- VTEX 4.53
- OCS N/A
- 52 Week Low
- VTEX $3.92
- OCS $11.78
- 52 Week High
- VTEX $7.58
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- VTEX 34.73
- OCS 50.18
- Support Level
- VTEX $3.97
- OCS $16.00
- Resistance Level
- VTEX $4.14
- OCS $17.34
- Average True Range (ATR)
- VTEX 0.12
- OCS 0.41
- MACD
- VTEX 0.08
- OCS 0.08
- Stochastic Oscillator
- VTEX 56.14
- OCS 66.67
About VTEX VTEX
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.